Recent clinical trials assessing the efficacy and safety of anti‐PD‐1/PD‐L1 antibody blockade suggest that higher PD‐L1 expression by patient cancer cells was associated with higher objective responses 3, 44. Here, PDCD1 is linked to cancer.